Editing Daiichi Sankyo Company, Limited
The edit can be undone. Please check the comparison below to verify that this is what you want to do, and then publish the changes below to finish undoing the edit.
Latest revision | Your text | ||
Line 190: | Line 190: | ||
=== 3ADC Conclusion === | === 3ADC Conclusion === | ||
In conclusion, Daiichi Sankyo is developing a '''wide range''' of '''cancer-targeting drugs''', with a primary focus on breast | In conclusion, Daiichi Sankyo is developing a '''wide range''' of '''cancer-targeting drugs''', with a primary focus on breast cancer, with Dato-DXds targeting hormone receptor positive, HER2 low or HER2 negative breast cancer, and triple negative breast cancer. T-DXds (such as ENHERTU®) targeting HER2 positive breast cancer, particularly when a patient has received prior anti-HER2 treatment. HER3-DXds targeting EFGR-positive NSCLC, and particularly in cases where the patient has become resistant to first-line treatments (such as EGFR TKIs). | ||
== Leadership == | == Leadership == |